GLP-1 receptor agonist
Type 2 diabetes: efficacy, safety, and tolerability of oral Semaglutide added to Insulin with or without Metformin: The PIONEER 8 trial
The aim of study was to investigate the efficacy, safety, and tolerability of oral Semaglutide ( Rybelsus ) added to...
Dulaglutide in combination with an SGLT-2 inhibitor improves blood glucose control in people with type 2 diabetes
Dulaglutide ( Trulicity ) significantly improves A1C ( average blood sugar concentration over two to three months ) when added...
Lixisenatide slows or prevents damage to the kidneys in patients with type 2 diabetes and cardiovascular disease
New research presented at the annual meeting of the European Association for the Study of Diabetes ( EASD ) has...
Adults with type 2 diabetes mellitus: Semaglutide has demonstrated superior improvements in glycaemic control vs Sitagliptin and Exenatide ER in two clinical trials
Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at...
Management of type 2 diabetes mellitus: basal Insulin and glucagon-like peptide-1 receptor agonist combination treatment
Combination treatment with a glucagon-like peptide-1 ( GLP-1 ) agonist and basal Insulin has been proposed as a treatment strategy...
Type 2 diabetes mellitus: incidence of pancreatitis among patients using incretins is low and that the drugs do not increase the risk of pancreatitis
A systematic review and meta-analysis has investigated the risk of pancreatitis associated with the use of incretin-based treatments in patients...
When patients with type 2 diabetes mellitus start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 ( GLP-1...
The FDA ( Food and Drug Administration ) has approved Saxenda ( Liraglutide [ rDNA origin ] injection ) as...
The FDA ( Food and Drug Administration ) has approved the New Drug Application ( NDA ) for Saxenda (...
Lixisenatide plus oral antidiabetics improves glycemic control in older patients inadequately controlled on oral antidiabetics
The efficacy and safety of Lixisenatide ( Lyxumia ), a once-daily prandial glucagon-like peptide-1 ( GLP-1 ) receptor agonist, in...
AWARD-2 and AWARD-4 trials: positive results of Dulaglutide, compared to Insulin glargine, in type 2 diabetes
Positive top-line results of two additional phase III AWARD trials for Dulaglutide, an investigational, long-acting glucagon-like peptide 1 ( GLP-1...
Sanofi-Aventis has announced that Lixisenatide ( Lyxumia ) once-daily achieved primary efficacy endpoint and fewer hypoglycemias versus Exenatide ( Byetta...
- Gad Anxiety
- Gallbladder Disease
- Gardenia Extract
- Gastric Adenocarcinoma
- Gastric Cancer
- Gastrointestinal Bleeding
- Gastrointestinal Stromal Tumor
- Gastro-Oesophageal Junction Adenocarcinoma
- Gaucher Disease